Glucotrack Welcomes New VP of Clinical Operations
![Glucotrack Welcomes New VP of Clinical Operations](https://investorshangout.com/images/blog/ihnews-Glucotrack%20Welcomes%20New%20VP%20of%20Clinical%20Operations.jpg)
Glucotrack Expands Leadership Team with New VP of Clinical Operations
Glucotrack, Inc. (Nasdaq: GCTK) is strengthening its leadership team by appointing Sandie Martha as the new Vice President of Clinical Operations. This move is aimed at bolstering the Company’s clinical trial capabilities for its continuous blood glucose monitor, enhancing the support provided to individuals living with diabetes.
Expertise in Clinical Trials
Sandie Martha brings over two decades of experience in clinical research encompassing both medical technology and drug development. Her proficiency includes leading various phases of clinical trials, which involves protocol development, execution, and training. She has an exceptional track record of successfully navigating projects through the complex clinical lifecycle.
Previous Roles and Accomplishments
Before joining Glucotrack, Ms. Martha served as Vice President of Clinical Affairs at Glysens, where she directed planning and execution of clinical trials for an innovative implantable continuous glucose monitor, showcasing her ability to drive advancements in glucose-monitoring technologies.
Commitment to Innovation in Diabetes Management
Ms. Martha's career also includes significant clinical operations roles at well-known organizations such as Dexcom and Intersection Medical, allowing her to gain substantial insight into the needs of diabetes management. She holds a Master of Science in Physiology from San Diego State University and a Bachelor of Science in Biological Sciences from the University of Miami.
Role and Responsibilities
In her role at Glucotrack, Ms. Martha will oversee the execution of the Company’s Clinical Trial Program. This includes collaborating with Contract Research Organizations (CROs), clinical centers, and investigators while developing comprehensive clinical protocols. Additionally, she will manage the oversight of data collection, analysis, and reporting for regulatory submissions.
Passion for Improving Diabetes Management
Expressing her motivation, Ms. Martha stated, "Having seen loved ones struggle with their diabetes management, I am passionate about the potential for advanced glucose monitoring technologies. The real-time continuous blood glucose data provided by Glucotrack's CBGM allows for a less intrusive approach, significantly enhancing the quality of life for those with diabetes. I am excited to join the Glucotrack leadership team to bring this innovative technology to market."
About Glucotrack, Inc.
Founded to focus on the design, development, and commercialization of novel diabetes management technologies, Glucotrack, Inc. (NASDAQ: GCTK) is currently developing a long-term implantable continuous blood glucose monitoring system aimed at improving the lives of individuals with diabetes.
Continuous Blood Glucose Monitoring System
The Glucotrack CBGM is designed to measure blood glucose levels continuously with a sensor that has a longevity of over two years. This system does not require on-body wear and operates with minimal calibration, thus ensuring a seamless experience for users.
Company Contact Information
For inquiries and further information about Glucotrack’s innovative solutions for diabetes management, interested parties can reach out via email:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
Frequently Asked Questions
What is the role of Sandie Martha at Glucotrack?
Sandie Martha is the new Vice President of Clinical Operations, responsible for leading the company's Clinical Trial Program and overseeing clinical studies.
What is the Glucotrack Continuous Blood Glucose Monitor?
The Glucotrack CBGM is a long-term, implantable system designed to continually measure blood glucose levels with minimal calibration, providing users with an advanced monitoring solution.
Why is continuous glucose monitoring important?
Continuous glucose monitoring provides real-time data, allowing individuals with diabetes to manage their condition more effectively and improve their quality of life.
What is the experience of Sandie Martha in the clinical field?
Sandie Martha has over 20 years of experience in clinical research, focusing on medical technology and drug development, with a strong background in leading clinical trials.
How does Glucotrack contribute to diabetes management?
Glucotrack develops innovative technologies that help individuals manage their diabetes more effectively, aiming to reduce the struggles associated with traditional glucose monitoring methodologies.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Harvard Apparatus Regenerative Technology Welcomes New Director
- Novonesis Enhances Profitability and Sales Projections for 2024
- Analysis of Rising Grocery Prices and Economic Impacts
- Market Anticipation Builds Ahead of Nvidia Earnings
- N2OFF Inc. Secures PV Solar Project Approval in Germany
- HYCU R-Cloud™ Enhances Data Protection with Microsoft Entra ID
- CenExel Names Patrick McLaughlin as New COO
- Exploring the Robust Growth of the IoT Market
- ibex Appoints Andreas Wilkens as New CTO
- Armlogi Expands Warehouse Operations at Port of Savannah